{"a":[{"_":"AstraZeneca’s Etcamah flunks first-line breast cancer trial, adding to oral SERDs’ failure record","$":{"href":"/pharma/astrazeneca-etcamah-flunks-first-line-breast-cancer-trial-adding-oral-serds-failure-record","hreflang":"en"}}]}
Phase 3negativeEtcamahgiredestrantNegative
AI Analysis
Summary
AstraZeneca's Etcamah failed to meet efficacy endpoints in a first-line HR+/HER2- breast cancer trial, joining Roche's giredestrant in missing clinical expectations for oral SERDs in this indication.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Etcamah failed to meet efficacy expectations in first-line HR+/HER2- breast cancer trial
Importance:8/10
Sentiment:
-0.95
clinical-failurebreast-canceroral-SERDfirst-lineHR+/HER2-
Related Companies
Read the original article
Published by FiercePharma on September 12, 2026 12:07 PM